Skanskaas sigigned a contract with Continuus Pharmaceuticals to build a pharmaceutical manufacturing facility in Woburnrn, Massachusetts, USA. The contract is worth USD 125 million, about SEK 1.1 billion, which will be included in the US order bookings for the fourth quarter 2021. The contract includes the renovation and building of a new 50,000 square foot (about 4,500 square meter) cGMP manufacturing facility in an existing shell space. The new facility will produce both dry active pharmaceutical ingredients (API) and finished drug products (DP) in both sterile injectable and tablet forms. The facility is being developed to produce three critical care medicines and one additional key drug with flexibility for future growth.